相关实验视频

Updated: Sep 19, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

合成的CAR T细胞被设计为持续提供所需的蛋白质

Sherri L Newmyer¹, Harikrishnan Radhakrishnan¹, Harold S Javitz²

¹Biosciences Division, SRI International, Menlo Park, CA 94025, United States of America.

Journal of controlled release : official journal of the Controlled Release Society

|June 16, 2025

概括

研究人员设计了具有仿真抗原受体 (CAR) 的小鼠T细胞,用于特定位点的蛋白质合成. 这种CAR T细胞平台可以在免疫能力模型中进行评估,从而推进癌症治疗研究.

科学领域:

免疫学免疫学免疫学
细胞疗法细胞疗法
生物技术是生物技术.

背景情况:

目前基于细胞的治疗评估经常使用免疫缺陷小鼠与异种移植,限制免疫微环境的洞察力.
需要先进的平台来评估在功能完善的免疫系统中的治疗疗效.

研究的目的:

为了工程初级小鼠T细胞与仿真抗原受体 (CARs) 特定位置的蛋白质表达.
调整一个人类T细胞CAR平台,用于免疫能力强的同源性小鼠模型.
在相关瘤微环境中评估工程化CAR T细胞的疗效.

主要方法:

原始小鼠T细胞是使用lentiviral转导来表达CARs的.
产生CD4和CD8CAR T细胞子集并在体内进行评估.
研究了与膜结合的互白素15 (mbIL15) 的联合表达,以提高T细胞功能.

主要成果:

卡尔T细胞平台成功地从人类转化为小鼠T细胞.
改造的小鼠CAR T细胞在合成基因模型中显示出特定位点的蛋白质表达.
协同表达mbIL15改善了CAR T细胞的内积累和递送功能.

结论:

这种工程小鼠CAR T细胞平台提供了一个强大的系统,用于评估免疫能力强的宿主中基于细胞的疗法.
该平台有助于评估治疗性蛋白质有效性和与免疫相关的毒性.
这种方法推进了CAR T细胞疗法的临床前评估,超出了传统的异种移植模型.

关键词:

在CAR T细胞中,基于细胞的药物递送是以细胞为基础的.具有免疫能力的小鼠模型.介质蛋白-15 介质蛋白-15 工程T细胞工程T细胞工程 T细胞的持久性

更多相关视频

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...